The starting point is not a skincare study at all. Biochemist Loren Pickart, working on his PhD at the University of California, San Francisco, was investigating why blood plasma from younger donors caused old human liver tissue to synthesise proteins more like young tissue, while plasma from older donors did not. Something in young plasma was carrying a signal, and Pickart set out to isolate it.

What he isolated from the albumin fraction of human plasma was a small tripeptide: glycine, L-histidine, and L-lysine, in that sequence. GHK. It was later established that GHK occurs naturally in human plasma, saliva, and urine, and that its concentration declines with age, from roughly 200 ng/mL around age 20 to below 80 ng/mL by age 60. The peptide's strong natural affinity for copper(II) ions was identified soon after, giving rise to the complex most people now recognise: GHK-Cu.

A decade separates the initial isolation from anything resembling the mechanism understood today. Between 1979 and 1984, working at the Benaroya Institute in Seattle, Pickart's group worked out the copper connection in more detail, and by 1983 there were the first laboratory indications that the copper-bound form specifically was what triggered wound-healing activity, not the peptide alone.

The mechanistic claim that gets repeated most often today, that GHK-Cu stimulates collagen synthesis at picomolar to nanomolar concentrations, traces to a 1988 fibroblast culture study published in FEBS Letters by Maquart, Pickart, and colleagues at the University of Reims. This is a genuinely unusual finding: most cosmetic actives need micromolar to millimolar concentrations to produce a measurable effect in cell culture. A picomolar effect is several orders of magnitude more potent, and it is one of the reasons GHK-Cu attracted sustained academic interest rather than fading as a one-off observation.

In 1985, Pickart co-founded ProCyte Corporation specifically to develop and commercialise copper peptide technology for wound healing and hair restoration. ProCyte went public in 1989. Pickart left the company in 1991 and, in 1992, founded a second company, Skin Biology, to continue the research independently and to develop a more stable second-generation copper peptide complex.

This detail matters for a reason that has nothing to do with efficacy: ProCyte's patent on cosmetic uses of GHK-Cu expired in May 2004. That expiry is a significant part of why the ingredient became widely available across the skincare market from the mid-2000s onward, rather than remaining locked to a single manufacturer. A crowded, competitive ingredient market is not itself evidence of efficacy, but it does explain the timeline of GHK-Cu's spread into mainstream cosmetics separately from the timeline of its research.

A cell-culture result does not automatically translate to a living organism, and the 1993 confirmation of the collagen-stimulating effect in rat wound models, again from Maquart and colleagues, is the study that closes that particular gap for this specific claim. It is an animal model, not a human trial, but it is the piece that moved the collagen-synthesis finding from "true in a dish" to "true in living tissue undergoing repair."

A pair of studies from Siméon and colleagues, published in 1999 and 2000, moved the research past "stimulates collagen" into a more complete picture of how GHK-Cu affects skin remodelling. These studies established that GHK-Cu does not simply push collagen production up. It modulates matrix metalloproteinase activity and their inhibitors in a more balanced way, meaning it affects the turnover of skin matrix components rather than acting as a one-directional stimulant. This distinction matters because unregulated collagen stimulation is not automatically desirable; balanced remodelling, where old and damaged matrix is cleared as new matrix is built, is closer to how healthy tissue actually behaves.

Establishing that a compound is biologically active in a dish or on a wound is a different question from establishing that it reaches its target when applied topically to intact skin, which is how most people actually use a GHK-Cu serum. The 2010 human skin penetration study from Hostynek and colleagues is the foundational reference here: using dermatomed human skin over a 48-hour exposure window, it established that meaningful copper delivery from a topical GHK-Cu application is achievable, and the authors explicitly framed their finding as relevant to whether topical application could serve as an alternative to injection.

A separate 2015 study out of the National University of Singapore looked at delivery through microneedling specifically, using intact skin over a much shorter 9-hour window. The two studies used different skin preparations and exposure times, which explains why their absolute figures differ; both are worth knowing about rather than picking whichever number sounds better. Neither study is a substitute for the other, and a proper account of GHK-Cu's delivery profile has to include both.

The most recent major expansion of the GHK-Cu evidence base came from computational gene expression analysis rather than new wet-lab experiments. A 2015 review from Pickart, Vasquez-Soltero, and Margolina catalogued GHK's role as a modulator across multiple cellular pathways involved in skin regeneration. A 2018 follow-up used the Connectivity Map database, a large public repository of gene expression signatures, to identify that GHK is capable of up- or down-regulating roughly 4,000 human genes.

That "4,000 genes" figure is genuinely real and genuinely well cited, but it is also the single most commonly overstated claim in GHK-Cu marketing, because the finding is a computational signature-matching analysis, not a measurement taken in living tissue. We've written a full breakdown of what that distinction means and doesn't mean in GHK-Cu's "4,000 Genes" Claim Is Real. The Marketing Built on It Isn't.

Fifty years of mechanistic research doesn't by itself constitute a formal safety assessment, and that gap was closed in 2018 when the Cosmetic Ingredient Review panel, an independent body that evaluates cosmetic ingredient safety in the United States, published its assessment of Tripeptide-1 (the INCI name for GHK) and related copper complexes. The panel's conclusion was that the ingredient is safe as used in cosmetic formulations, though the review did not extend to reproductive or developmental toxicity, a gap worth knowing if that's a relevant consideration for you. We've covered this review and what it does and doesn't establish in more detail in Why GHK-Cu Passed a Formal Safety Review.

One of the more interesting recent developments has nothing to do with GHK-Cu specifically. Since 2022, there has been a substantial expansion in the broader scientific understanding of copper's role in cell biology, including the discovery and characterisation of cuproptosis, a distinct form of copper-dependent cell death identified in mainstream cell biology research. GHK-Cu research was built for decades on the premise that copper delivery to tissue matters mechanistically, well before the wider field had this level of detail on why. That doesn't retroactively validate any specific GHK-Cu claim, but it is a useful piece of context: copper's role in cell biology turned out to be more significant, not less, as the surrounding science matured. We go into this in more depth in Copper in Biology: Why the Ion Matters as Much as the Peptide.

Fifty years is a genuinely unusual amount of continuous research attention for a cosmetic active, and the picture that emerges is more coherent than most: an isolation study, a mechanism, an in vivo confirmation, a delivery study, a formal safety review, and a wide gene-expression survey, each building reasonably directly on the last. That is a stronger foundation than the large majority of ingredients on a skincare shelf can claim.

What it does not include is a large-scale, placebo-controlled human clinical trial measuring visible skin outcomes from a finished topical GHK-Cu product over a defined period, the kind of study that exists for some prescription actives. Small human studies on GHK-containing cosmetic formulations do exist, including comparative work against other actives, but they tend to share the same limitations: small sample sizes, a specific proprietary formulation rather than GHK-Cu in isolation, and no placebo control. Much of the rest of the evidence base is built from fibroblast cultures, animal wound models, human skin penetration studies, and computational gene analysis. Each of those is a legitimate and useful piece of evidence. None of them, individually or combined, is equivalent to a well-powered human efficacy trial for a cosmetic serum.

Knowing this trail matters most when you're actually evaluating a product against it. A stated concentration, a clean INCI position, and a formulation that reflects what the research used are what separate a serum built around this history from one that's simply borrowing the name. Our GHK-Cu buyer's guide walks through exactly what to look for.

AmpleLab's 1% GHK-Cu Face and Skin Serum is formulated at a stated, disclosed concentration in a glycol-free carrier for exactly that reason: fifty years of research is only useful to a buyer if the product in front of them can actually be checked against it.

AmpleLab products are cosmetic formulations registered on the UK Cosmetic Products Notification Portal. They are not medicines and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Research references are provided for informational purposes and do not constitute clinical claims.

AmpleLab.